Round 1

Reviewer 1 Report

Well done

Should be add new o update articles such as

Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients

Atsunori Kashiwagi,

Corresponding Author

• [email protected]

• orcid.org/0000-0002-6049-3236

Kusatsu General Hospital, Kusatsu, Japan

Correspondence

Atsunori Kashiwagi

Tel.: +81-77-563-8866

Fax: +81-77-565-9313

E-mail address: [email protected]

Search for more papers by this author Shinchi Araki,

• orcid.org/0000-0002-2933-0316

Department of Medicine, Shiga University of Medical Science, Otsu, Japan

Search for more papers by this author Hiroshi Maegawa,

• orcid.org/0000-0002-4611-8149

Department of Medicine, Shiga University of Medical Science, Otsu, Japan

Search for more papers by this author Atsunori Kashiwagi,

Corresponding Author

• [email protected]

• orcid.org/0000-0002-6049-3236

Kusatsu General Hospital, Kusatsu, Japan

Correspondence

Atsunori Kashiwagi

Tel.: +81-77-563-8866

Fax: +81-77-565-9313

E-mail address: [email protected]

Search for more papers by this author Shinchi Araki,

• orcid.org/0000-0002-2933-0316

Department of Medicine, Shiga University of Medical Science, Otsu, Japan

Search for more papers by this author Hiroshi Maegawa,

• orcid.org/0000-0002-4611-8149

Department of Medicine, Shiga University of Medical Science, Otsu, Japan

Search for more papers by this author First published: 20 June 2020 https://doi.org/10.1111/jdi.13329     Annu Rev Pharmacol Toxicol Actions

• Search in PubMed
• Search in NLM Catalog
• Add to Search

. 2021 Sep 13. doi: 10.1146/annurev-pharmtox-052120-014725. Online ahead of print.

Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure

Kevin S Shah  ¹ , James C Fang  ¹ Affiliations Expand      

Affiliation

• ¹ Division of Cardiovascular Medicine, University of Utah Health, Salt Lake City, Utah 84132, USA; email: [email protected], [email protected].

• PMID: 34516288
• DOI: 10.1146/annurev-pharmtox-052120-014725
  
  
     * This paper is a original one
     * Excellent work
     * Perhaps add 1 or 2 new update reference

Author Response

Comments and Suggestions for Authors

Well done

 Should be add new o update articles such as

 Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients

Atsunori Kashiwagi,

Corresponding Author

• [email protected]
• org/0000-0002-6049-3236

Kusatsu General Hospital, Kusatsu, Japan

Correspondence

Atsunori Kashiwagi

Tel.: +81-77-563-8866

Fax: +81-77-565-9313

E-mail address: [email protected]

Search for more papers by this author Shinchi Araki,

• org/0000-0002-2933-0316

Department of Medicine, Shiga University of Medical Science, Otsu, Japan

Search for more papers by this author Hiroshi Maegawa,

• org/0000-0002-4611-8149

Department of Medicine, Shiga University of Medical Science, Otsu, Japan

Search for more papers by this author Atsunori Kashiwagi,

Corresponding Author

• [email protected]
• org/0000-0002-6049-3236

Kusatsu General Hospital, Kusatsu, Japan

Correspondence

Atsunori Kashiwagi

Tel.: +81-77-563-8866

Fax: +81-77-565-9313

E-mail address: [email protected]

Search for more papers by this author Shinchi Araki,

• org/0000-0002-2933-0316

Department of Medicine, Shiga University of Medical Science, Otsu, Japan

Search for more papers by this author Hiroshi Maegawa,

• org/0000-0002-4611-8149

Department of Medicine, Shiga University of Medical Science, Otsu, Japan

Search for more papers by this author First published: 20 June 2020 https://doi.org/10.1111/jdi.13329     Annu Rev Pharmacol Toxicol Actions

• Search in PubMed
• Search in NLM Catalog
• Add to Search

. 2021 Sep 13. doi: 10.1146/annurev-pharmtox-052120-014725. Online ahead of print.

Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure

Kevin S Shah  ¹ , James C Fang  ¹ Affiliations Expand      

Affiliation

• ¹Division of Cardiovascular Medicine, University of Utah Health, Salt Lake City, Utah 84132, USA; email: [email protected], [email protected].
• PMID: 34516288
• DOI: 10.1146/annurev-pharmtox-052120-014725
  
  
   * This paper is a original one
     * Excellent work
     * Perhaps add 1 or 2 new update reference

RESPONSE: Thank you for your comments. We have added some new updated references as per your suggestion.

Reviewer 2 Report

The authors have made a great attempt at describing the effects and management of SGLT2 in diabetics. The topic is significant to the field and will add to a valuable article. However, the manuscript does not seem to be ready for publication and needs significant changes.

• The review needs to be more structured to give clear and detailed information in a categorized way. Including a few subheadings to add groups of topics or perhaps using the heading such as in their figures might be helpful in making the review a good read.
• Figures are low quality and need to be made with higher resolutions images and clear labelling, clear text, scale adjustment etc.
• Figure legends need to be more elaborated and should be explanatory in a way that the readers can get a clear idea what authors are trying to say. I am not able to understand figure 2. Did the authors intend to add the SGLT2 inhibitors? Adding the red cross indicates the removal of SGLT2 inhibitors. Please check.
• Authors have talked about the genetic factors that make east Asians more susceptible to diabetes related complications. It would be interesting to mention some important ones and explain in brief.
• It would be interesting to talk in the initial part of the review about the major molecular mechanisms that play role in SGLT2 pathway and which get affected by the inhibitor. For example, they have talked about different drug therapies, how do they differ in their action and what makes one more effective than the other. It would also be important not to forget about the side effects and talk about those here as well. 
• Minor English/writing corrections are needed such as removing repetitive words from the table, language in a couple of headings and a few typos.

Author Response

• The review needs to be more structured to give clear and detailed information in a categorized way. Including a few subheadings to add groups of topics or perhaps using the heading such as in their figures might be helpful in making the review a good read

RESPONSE: We have updated as per your suggestion.

• Figures are low quality and need to be made with higher resolutions images and clear labelling, clear text, scale adjustment etc.

RESPONSE: We have updated the image with higher resolution with 300 dpi.

• Figure legends need to be more elaborated and should be explanatory in a way that the readers can get a clear idea what authors are trying to say. I am not able to understand figure 2. Did the authors intend to add the SGLT2 inhibitors? Adding the red cross indicates the removal of SGLT2 inhibitors. Please check.

RESPONSE: Thank you for your comments & suggestions. Changes has been made as per your suggestion.

• Authors have talked about the genetic factors that make east Asians more susceptible to diabetes related complications. It would be interesting to mention some important ones and explain in brief.

RESPONSE: Thank you for your comments & suggestions. We have added related subtopic as  per your suggestion.

• It would be interesting to talk in the initial part of the review about the major molecular mechanisms that play role in SGLT2 pathway and which get affected by the inhibitor. For example, they have talked about different drug therapies, how do they differ in their action and what makes one more effective than the other. It would also be important not to forget about the side effects and talk about those here as well.

RESPONSE: Thank you for your comments & suggestions. We have updated as  per your suggestion.

• Minor English/writing corrections are needed such as removing repetitive words from the table, language in a couple of headings and a few typos.

RESPONSE: Changes has been done.